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Awareness and Attitudes about 
Disease Mongering among Medical 
and Pharmaceutical Students 
C. Jairaj Kumar, Abhizith Deoker, Ashwini Kumar, 
Arunachalam Kumar, B. M. Hegde
Pharmaceutical companies throughout the world market 
their products aggressively through a variety of promotional 
campaigns [1]. In India, these marketing practices pose a 
greater problem because the restrictions on drug dispensing 
are very limited—drugs often being dispensed without a 
prescription from a licensed physician. The companies take 
full advantage of this situation. As many patients in India 
are poor and illiterate, and lack information on health care, 
they often visit local pharmacists or quacks for medical 
advice. Pharmacists routinely dispense drugs illegally over 
the counter. We visited 40 local pharmacy stores for medical 
advice for a feigned medical ailment, and we found that 
all 40 pharmacists dispensed drugs, including expensive 
antibiotics [2]. 
Pharmaceutical promotional campaigns in India, unlike 
those in developed countries (where pharmacists have little 
inﬂ uence on drug sales), are not only aimed at changing 
the prescribing habits of physicians but also at pharmacists 
and quacks. Pharmaceutical companies in India offer 
various schemes and incentives (including television sets, 
motorcycles, and the opportunity for higher proﬁ t margins) 
to lure pharmacists into buying more drugs than they would 
normally need. As a result, the pharmacists make every effort 
to sell these drugs to patients visiting them for medical advice. 
They may also associate themselves with quacks or physicians 
in their efforts to shift their stock of the drugs. 
In developed countries, dubious pharmaceutical marketing 
practices would soon attract the attention of watchdog bodies 
and social activists, but in India they go undetected. We 
believe that this situation demands proactive action on the 
part of the medical profession and also of the government. 
The efforts of the pharmaceutical industry to medicalize 
human life should be resisted. We do not wish India to be 
in the same position as the countries of the West, where 
adverse drug reactions are responsible for a signiﬁ cant 
proportion of hospital admissions and require millions of 
outpatient visits and corrective measures. In the United 
States, for example, there are about 100,000 deaths due 
to medical errors every year, of which about 7,000 are 
attributed to drug reactions [3].
We believe it is important to assess current awareness about 
disease mongering among medical and pharmaceutical 
students, as pharmaceutical promotional campaigns are 
aimed at both professions. Assessing current awareness 
could provide a basis for further research, leading to the 
development of effective measures that will raise awareness 
levels and motivate students to participate in future 
campaigns that seek to combat disease mongering. 
Most medical and pharmaceutical students in India are 
not aware of the issue of disease mongering; neither do 
most of them know that recent audits have shown medical 
interventions and adverse drug reactions to be major causes 
of death and disability in the US [4].
Articles have been published warning the profession 
about disease mongering [5–7], but for the most part 
these warnings have not been heeded. One is reminded of 
Aristotle, who so rightly observed that “truth could inﬂ uence 
only half a score of men in a century, while falsehood and 
mystery would drag millions by the nose.” 
We prepared a 20-item questionnaire (Text S1) about 
disease mongering and the inﬂ uence of the drug industry 
on clinical practice. The questionnaires were distributed 
among a random sample of 250 ﬁ nal-year medical and 250 
ﬁ nal-year pharmaceutical students. The overall response rate 
was 406 out of 500 (81.2%), comprising 199 medical and 207 
pharmaceutical students. Of the medical students, 30 out 
of 199 (15%) were able to explain disease mongering with 
relevant examples. Of the pharmaceutical students, 114 out 
of 207 (55%) were able to do so, suggesting that awareness 
of the problem was much greater among these students. 
Interestingly, however, 87 out of 114 pharmaceutical students 
believed the government, not the pharmaceutical industry, 
was responsible for the problem. 
All the students, both medical and pharmaceutical, 
said they had frequently seen drugs dispensed without 
prescription. They had also often seen patients visit local 
pharmacists for medical advice. They agreed that both 
practices were unethical. However, both the medical and 
the pharmaceutical students were unaware of the incentives 
offered by drug companies to pharmacists for buying their 
drugs, which lead to unethical dispensing. 
We believe that our small project, despite its inherent 
limitations, has thrown some light on the situation. 
Pharmaceutical students, who are exposed to the drug 
industry to some extent during their studies, have some 
idea of the magnitude of the problem, while the majority 
of medical students have no idea that even their textbooks 
are written with the help of money that comes from drug 
companies [8]. We need to make a more concerted attempt 
to educate the student community of all the health-care 
professions, in order to counter this unfair tendency. The 
government should undertake major initiatives to ensure 
that drugs are only dispensed with a prescription from 
a licensed physician. Medical associations and medical 
college administrators should alert their members to 
cross-check the information provided in drug company 
literature. Medical students should be warned about disease 
mongering through the display of posters, and through the 
organization of essay competitions and interactive plays. 
Students can play a further role by conducting regional and 
national surveys of the awareness of the public concerning 
this serious issue. 
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Text S1. 20-Item Questionnaire about Disease Mongering and the 
Inﬂ uence of the Drug Industry on Clinical Practice
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Syphilis: A Forgotten Priority
Damian Walker, Godfrey Walker
Peter Hotez and colleagues [1] provide a persuasive case for 
incorporating a rapid-impact package for “neglected tropical 
diseases” with programs for HIV/AIDS, tuberculosis, and 
malaria as part of a pro-poor strategy for improving health in 
the developing world. However, we believe there is a disease 
that has a high claim to be included in partnerships and 
initiatives devoted to what the authors term the “Big Three”, 
and yet has been largely ignored. 
On the basis of the criteria identiﬁ ed by Hotez et al., the 
case for giving explicit priority to programs to control syphilis 
and particularly congenital syphilis is high [2]. In 2002, there 
were 157,000 deaths contributing to more than 4 million 
disability-adjusted life years (DALYs) (see annex tables 2 and 
3 in [3]). These estimates exclude the burden attributable 
to maternal syphilis, which includes 460,000 abortions or 
stillbirths, 270,000 low-birth-weight babies, and 270,000 
cases of congenital syphilis each year [4]. This burden is 
concentrated in Africa and exhibits considerable geographic 
overlap with HIV infection. Syphilis accounts for 20% of 
genital ulcer diseases and is a cofactor in transmission of HIV, 
and both infections appear to progress more rapidly when 
they occur together [5]. 
Infection with syphilis is curable, and control is possible 
with existing drugs (speciﬁ cally penicillin). However, little 
attention has been given to this in context of the Big Three. 
Azithromycin is included in the chemotherapy package 
proposed by Hotez et al. for the control of trachoma, and 
there are clear synergies with syphilis control. A recent 
trial in Tanzania demonstrated that a single dose of oral 
azithromycin is as effective as injectable penicillin G 
benzathine in treating early and latent syphilis [6]. However, 
some caution is needed concerning the widespread use of 
azithromycin for syphilis in view of the recent emergence of 
azithromycin-resistant Treponema pallidum [7]. 
There are other possible synergies in having a strategy 
including syphilis control; e.g., during routine antenatal 
care, chemotherapy for soil-transmitted helminths could be 
provided at the same time as offering voluntary counselling 
and testing (VCT) for HIV infection and screening for 
maternal syphilis. The control of syphilis has been shown 
to be highly cost-effective. If the control of syphilis was 
integrated into programs dealing with the four priority 
disease groups advocated by Hotez et al., then the cost-
effectiveness of tackling not only syphilis but also the 
other four major public health priorities would improve. 
Furthermore, it would lessen the chance of avoiding death 
from one disease but dying from another [8]. 
While it might be hoped that the case for giving priority 
to syphilis would have been accepted and explicit emphasis 
given to programs to control this disease, this has not 
happened. Unfortunately, limited attention is given to syphilis 
control as part of the several partnerships devoted to the Big 
Three. Maybe this is because syphilis has historically had a 
social stigma, and has, therefore, been neglected. Now is the 
time to change this as part of a pro-poor strategy to meet the 
Millennium Development Goals. We suggest it is explicitly 
included in the rapid-impact package for neglected tropical 
diseases. 
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Authors’ Reply
Damian Walker and Godfrey Walker [1] make a strong 
case for adding congenital syphilis to our proposed list of 
neglected tropical diseases (NTDs). Indeed, we would hasten 
to add all of the major treponemal infections—including 
yaws, endemic syphilis (bejel), and pinta—could potentially 
qualify as NTDs. Leptospirosis and bartonellosis might also 
qualify as important neglected bacterial infections, while 
amoebiasis is an important yet neglected protozoan infection. 
Therefore, it is possible that in the future our list of 13–15 
NTDs could expand to approximately 20 conditions. In the 
meantime, we are working to establish a set of consensus 
guidelines for this important list of NTDs. 
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The Need for an Individual Approach 
to Lung Cancer Treatment
Hisayuki Shigematsu, Shinichi Toyooka, Makoto 
Suzuki
Heidi Greulich and colleagues [1] have demonstrated 
the signiﬁ cance of insertion mutations in the epidermal 
growth factor receptor (EGFR) (exon 20) for tumorigenesis 
and responsiveness to tyrosine kinase inhibitors (TKIs) in 
lung cancers. They reported that different types of EGFR 
mutations conveyed different sensitivity to TKIs. Although 
several previous studies have suggested that tumors harboring 
mutations in the EGFR kinase domain were sensitive to TKIs 
such as geﬁ tinib or erlotinib [2,3], others had reported an 
association between the T790M mutation in exon 20 and 
the resistance to TKIs [4,5]. As we learn more about the 
relationship between EGFR status (including gene copy 
number, mutation status, and mutation type) and drug 
sensitivity, decisions about treatment with TKIs for patients 
with non-small-cell lung cancer (NSCLC) become more 
complex. 
Previously, we reported HER2 mutational status, as well 
as EGFR and KRAS, in a large number of NSCLCs [6]. 
We found that 22% of tumors had EGFR kinase domain 
mutations (149 out of 671). Of these 149, 15 of them were 
insertion mutations in exon 20. The more common types 
of mutations—i.e., deletion in exon 19 (68 out of 149) and 
L858R in exon 21 (61 out of 149)—were more frequent in 
women and in “never smokers” (with p values of less than 
0.001), whereas the exon 20 insertion mutations showed 
no bias for sex (seven in males versus eight in females) 
or smoking status (seven in smokers versus eight in never 
smokers). We have no data regarding TKI sensitivity for the 
15 patients with insertion mutations to date, but based on the 
results from others and our own in vitro data, they may not 
beneﬁ t from the conventional TKIs, despite the fact that their 
tumors have EGFR kinase domain mutations. 
To maximize beneﬁ t to patients, we should determine the 
exact type of mutation for an individual tumor and determine 
whether it conveys sensitivity or resistance prior to TKI therapy. 
The development and clinical application of novel agents 
overcoming resistance should yield a more effective targeted 
therapy for tumors with all types of EGFR mutations. 
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Mischievous Odds Ratios
William Steinsmith
Pieter Reitsma and colleagues have explored—in a 
population of patients anticoagulated with coumarin 
congeners—the connection between the presence of mutant 
alleles of a single gene and the risk of haemorrhage [1].
Using as their denominator the odds for bleeding in a 
patient without mutant alleles, and using as their numerator 
the odds for patients with each of the two mutant alleles, the 
authors propose the resulting odds ratios as surrogates for the 
relative risk of haemorrhage.
It should be noted, however, that the conﬂ ation of an odds 
ratio with a relative risk is not generally justiﬁ ed [2,3]. The 
relative risk is the ratio of two probabilities (p2/p1), whereas 
the corresponding odds ratio is [p1/(1−p1)]/[p2/(1−p2)]. 
Equating these two ratios requires that p1 = p2, i.e., that the 
risk ratio be unity.
In Reitsma and colleagues’ paper, none of the eight 
odds ratios presented in Table 2 turn out identical with the 
corresponding calculated risk ratio, and the most discordant 
pair of values diverge by a factor of about 1.4, i.e., the odds 
ratio of 2.6 corresponding to a relative risk of 1.9.
Mischievous conﬂ ation of odds ratios with probability ratios 
is widespread in the literature dealing with laboratory testing, 
with the odds ratio (confusingly termed the “likelihood 
ratio”) typically presented as surrogate for the corresponding 
ratio of probabilities. 
The power of a positive laboratory test to enhance the 
likelihood of disease presence in a given patient (properly 
termed the “positive probability-based likelihood ratio”) is 
the ratio of two probabilities: the probability that the patient 
who tested positive is truly diseased (termed the “positive 
predictive value”) divided by the probability of disease in the 
pre-test population (termed the “disease prevalence”). 
Expressed explicitly in terms of the subcategories of the 
test population, the positive predictive value is the ratio 
represented by (True Positives)/(True Positives + False 
Positives), and the prevalence is the ratio represented by 
(True Positives + False Negatives)/(True Positives + False 
Negatives + True Negatives + False Positives). 
The calculus is easily adapted to compute the probability-
based likelihood ratio for the absence of disease in a given 
patient. In this case, the post-negative-test probability of 
disease absence (termed the “negative predictive value”) is 
the ratio represented by (True Negatives)/(True Negatives + 
False Negatives), and the pre-test probability is one minus the 
disease prevalence. The negative probability-based likelihood 
ratio is, then, the ratio represented by the post-test probability 
divided by the pre-test probability.
A more descriptive term for the probability-based 
likelihood ratio would be the “probability magnifying power,” 
since it leads to the expanded probability of the presence (or 
absence) of disease yielded by a positive (or negative) test 
result. 
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Authors’ Reply
William Steinsmith is correct that the odds ratio (OR) is used 
to approximate the relative risk, but incorrect that in this 
instance, and most other ones, the two would differ by more 
than a trivial amount, since he has failed to appreciate the 
case-control design.
Indeed, if the cumulative risk of disease is p1 in the 
exposed and p0 in the nonexposed, the relative risk (p1/
p0) only equates the OR, [p1/(1−p1)]/[p0/(1−p0)], when 
exposure confers no excess risk. However, in a case-control 
study, p1 and p0 cannot be directly estimated (nor, obviously, 
can their odds), and the OR is the only possible estimator 
(hence its frequent use).
We will illustrate the theory starting with a cohort study, 
and then moving from this to a case-control study. When 
risks are low, the OR will always be a good approximation of 
the relative risk because OR = (p1/p0)/[(1−p1)/(1−p0)], 
in which the second part of the term will be close to one. 
So, suppose a trait is present in 20% of a population, with 
a risk of disease of 1% in those without the trait, and 2.5% 
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in those with the trait, i.e., a relative risk of 2.5. These are 
likely to be close to the actual annual numbers for risk of 
haemorrhage under anticoagulant treatment with and 
without the VKORC1 variant [1,2]. If we follow 10,000 
people for one year—8,000 without the trait, of whom 80 will 
develop disease; 2,000 with the trait, of whom 50 will develop 
disease—RR = (50/2,000)/(80/8,000) = 2.5000, and OR = 
(50/1,950)/(80/7,920) = 2.5385.When the OR is written out 
in full to [(50/2,000)/(1,950/2,000)]/[(80/8,000)/(7920/8
000)], this can easily be reduced to the above.
In a case-control study, all cases are included, but there are 
only a fraction of all noncases (controls). With a sampling 
fraction of 1/10, the case-control study sampled from this 
cohort would look like the following: 80 cases without and 
50 cases with the trait, 792 controls without and 195 controls 
with the trait (OR = [50/195]/[80/792] = 2.5385).
With a sampling fraction of 1/100, there would be 79.2 
unexposed and 19.5 exposed controls, and the OR would 
still be 2.54. This demonstrates that the actual risk or odds of 
disease cannot be derived once only a sample of individuals 
without disease are included, but that the ratio of exposed 
over unexposed controls (195/792) remains valid whatever 
the sampling fraction. This has been called the “exposure 
odds”, and many prefer to write the OR as the exposure odds 
ratio: OR = (50/80)/(195/792) = 2.54.
In a cohort study, the OR can be easily recalculated into a 
risk ratio (RR), since the actual risks (p0 and p1) are known 
[3]: RR = OR/[(1−p0) + p0*OR] [3]. In the example above, 
RR = 2.5385/(0.99 + 0.01*2.5385) = 2.5000.
In a case-control study, because the number of controls is 
only a fraction of the actual number of individuals without 
disease in the cohort, absolute risks cannot be calculated, and 
a recalculation from OR to RR is not possible (unless there is 
external information on the absolute risks). 
This implies that it is not possible to calculate from our 
data how different the OR was from the RR, as Steinsmith 
tried. We can, however, in this particular case, make an 
estimate, since we know the risk of haemorrhage under 
anticoagulant treatment from previous studies to be around 
1% per year. With a background risk of 1% per year, all the 
ORs mentioned in our paper are within 2% of the relative 
risk. The highest OR of 2.6 (2.5641) would relate to a relative 
risk of 2.5 (2.5246)—a trivial difference. Steinsmith’s further 
suggestions for analyses, i.e., to use likelihood ratios, are 
relevant to studies of diagnostic tests in which the aim is to 
evaluate the presence or absence of disease. This is not the 
analysis one would use in aetiologic studies such as ours.
Generally, since most diseases are infrequent, ORs are 
good estimators of relative risks under this “rare disease 
assumption”. For a disease with a frequency of 10%, which 
is high, the difference between OR and RR is still only 10%. 
On a higher theoretical level, one could argue that the 
parameter to estimate is not the relative risk, but the rate 
ratio, i.e., the ratio of two incidence rates. While a cumulative 
risk is a probability, an incidence has time −1 as its unit, and 
lies between zero and inﬁ nity. Since the incidence rate is 
the basic measure of disease occurrence, the rate ratio is the 
prime comparator, to be preferred over relative risks (which, 
over time, will converge to unity, because, to quote John 
Maynard Keynes, “in the long run we are all dead”). It can 
be shown that under certain sampling conditions, i.e., when 
controls are sampled from a dynamic population, there is no 
need for the “rare disease assumption”, and the OR is the 
exact equivalent of an incidence rate ratio [4]. 
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